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Abstract
Osteoarthritis (OA) is a common joint disease that results from the disintegration of joint cartilage and the underlying
bone. Because cartilage and chondrocytes lack the ability to self-regenerate, efforts have been made to utilize stem
cells to treat OA. Although various methods have been used to differentiate stem cells into functional chondrocytes,
the currently available methods cannot induce stem cells to undergo differentiation into chondrocyte-like cells
without inducing characteristics of hypertrophic chondrocytes, which finally lead to cartilage disintegration and
calcification. Therefore, an optimized method to differentiate stem cells into chondrocytes that do not display
undesired phenotypes is needed. This study focused on differentiating adipose-derived stem cells (ASCs) into
functional chondrocytes using a small molecule that regulated the expression of Sox9 as a key factor in cartilage
development and then explored its ability to treat OA. We selected ellipticine (ELPC), which induces chondrocyte
differentiation of ASCs, using a GFP-Sox9 promoter vector screening system. An in vivo study was performed to
confirm the recovery rate of cartilage regeneration with ASC differentiation into chondrocytes by ELPC in a
collagenase-induced animal model of OA. Taken together, these data indicate that ellipticine induces ASCs to
differentiate into mature chondrocytes without hypertrophic chondrocytes in vitro and in vivo, thus overcoming a
problem encountered in previous studies. These results indicate that ELPC is a novel chondrocyte differentiation-
inducing drug that shows potential as a cell therapy for OA.
Introduction
Osteoarthritis (OA) is a major degenerative and com-
mon chronic joint disease caused mainly by aging1,2.
Moreover, OA has been observed in younger populations
due to systemic and genetic factors3–5. The articular
cartilage composed of chondrocytes and a dense extra-
cellular matrix (ECM) is a key component of joints that
have a limited capacity for intrinsic healing and repair6,7.
During the progression of OA, active ECM remodeling
occurs with environmental changes such as severe or
chronic inflammation, which in turn leads to the induc-
tion of the maturation of hypertrophic chondrocytes.
Hypertrophic chondrocytes characteristically overexpress
hypertrophic markers, runt-related transcription factor 2
(RUNX2), Type X collagen, Indian hedgehog, and
Transglutaminase-2. Hypertrophic chondrocytes are also
known to synthesize various matrix-degrading enzymes,
such as matrix metalloproteinase 13 (MMP13) and a
disintegrin and metalloproteinase containing thrombos-
pondin motifs (ADAMTS4, 5), which accelerate the
decomposition of the ECM, leading to cartilage loss and
calcification8,9
Although various methods from alternative medicine to
surgical procedures have been utilized for OA patients,
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there is no way to reverse the onset of this disease. The
most recent therapeutic approaches for OA involve the
use of stem cells10. Adipose-derived stem cells (ASCs)
have recently been widely used because they are easier to
obtain than bone marrow-derived stem cells11,12. How-
ever, previous studies have demonstrated that hyper-
trophic chondrocytes are a major problem in
differentiated chondrocytes using stem cells 13,14.
To regulate the expression of critical genes and proteins
involved in stem cell differentiation, previous studies have
used systems such as viral vectors, microRNAs, siRNAs,
and shRNAs. However, conventional systems have lim-
itations regarding cytotoxicity, delivery, and main-
tenance15–17. Therefore, we used small molecules that are
stable and transferable in the cells to control the expres-
sion of genes and proteins. Consequently, a new small
molecule-based method was used to screen for small
molecule drugs that could induce the differentiation from
ASCs into chondrocytes. Ultimately, the goal is to induce
the optimal differentiation of ASCs into mature chon-




bazole) was purchased from Enzo Life Science, Inc.
In–house chemical libraries, receptor agonists and
antagonist kinase inhibitors, and ion channel activators
and inhibitors were used18. Dulbecco’s modified Eagle’s
medium (DMEM), fetal bovine serum (FBS), and
penicillin-streptomycin were obtained from the same
corporation (Life Technologies, Grand Island, NY, USA).
For polymerase chain reaction (PCR), oligonucleotides
were synthesized by Bioneer (Bioneer, Daejeon, South
Korea), and RNA was extracted using chloroform and 2-
propanol (Sigma-Aldrich, St. Louis, MO, USA). Reverse
transcription for cDNA synthesis was conducted using a
reverse transcription system (Promega Corporation,
Madison, WI, USA), and PCR was performed with Ex
Taq, dNTP mixture (2.5 mM each), and 10x Ex Taq buffer
(TaKaRa Bio, Inc., Otsu, Japan). Western blot and
immunofluorescence antibodies were used to detect type
II collagen, aggrecan, type X collagen, p53, p-p53, and
β-actin (Santa Cruz Biotechnology, USA). Secondary
antibody usage was divided into 2 types: mouse or rabbit
(Enzo Life Sciences, Inc., Farmingdale, NY, USA) for
western blot analysis (horseradish peroxidase (HRP)-
conjugated) and mouse, rabbit, or goat (Jackson Immu-
noresearch Laboratories, West Grove, PA, USA; Vector
Laboratories, Burlingame, CA, USA; Abcam, USA) for
immunostaining (fluorescein isothiocyanate, FITC; phy-
coerythrin, PE; or allophycocyanin, APC-conjugated).
Western blotting detection systems were obtained from
GE Healthcare Life Sciences (Uppsala, Sweden), and 4′,6-
diamidino-2-phenylindole was obtained from Life
Technologies (USA).
Sox9 promoter gene assay
The promoter region for the sex-determining region Y-
type high mobility group box (Sox)9 (−1034 bp to
+67 bp) used in this study was based on the promoter
region described in DC Colter et al.19. The PCR product
of the promoter region was cloned into the pAcGFP1-1
vector. The conjugated Sox9 promoter GFP vector was
transfected into ASCs using the TransIT-X2 Dynamic
Delivery system. After transfection, the GFP intensity
was examined under fluorescence microscopy (Glomax®
Explorer multimode microplate reader, Promega,
WI, USA).
Animals
Adult 8-week-old Sprague-Dawley male rats were used
(Koatech, Pyeongtaek, Korea) from Harlan USA. All ani-
mal experimental procedures were approved by the
Institutional Animal Care and Use Committee, Catholic
Kwandong University College of Medicine, and the Asso-
ciation for Assessment and Accreditation of Laboratory
Animal Care and were performed in accordance with the
Guidelines and Regulations for Animal Care.
Adipose-derived stem cell culture
Human ASCs were purchased from Invitrogen (CA,
USA) and cultured in growth media (DMEM supple-
mented with 10% FBS, 100 unit/ml penicillin, and
100 μg/ml streptomycin) at 37 °C and 5% CO2. Experi-
ments used cells between passages 3 and 7 for
differentiation.
Pellet culture system
ASCs were cultured by an improved pellet culture sys-
tem described by Johnstone et al.20 When cartilage for-
mation proceeds in a stable and smooth manner, the
pellet will maintain a rounded shape while it grows. ASCs
(2.5 × 105) were centrifuged at 600×g for 5 min in a 15-ml
polypropylene tube. The resulting pellets were treated
with an ELPC final concentration of 1 μM in 10% FBS
DMEM for 16 days. The medium and the ELPC were
replaced with fresh medium and ELPC once every 3 days.
Cell viability assay
ASCs were plated in 96-well cell culture plates in triplicate
at 5 × 103 cells/well. After treatment with ELPC for 24 h or
48 h in ASCs, EZ-Cytox reagent (DoGEN, Seoul, Korea) was
added to each well and incubated at 37 °C for 2 h to react.
The sample absorbance was measured using a microplate
reader (Thermo Fisher Scientific, MA, USA) at 450 nm.
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Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol. Chloroform was
added to separate each sample into layers of RNA, DNA,
and proteins, and then, each sample was centrifuged at
12,000 rpm and 4 °C for 15min. Next, the RNA from each
sample was collected in a new tube, and 2-propanol was
added to obtain the pellet, after which the centrifugation
was repeated at 12,000 rpm at 4 °C for 10min. The pellet
was washed in 75% (v/v) ethanol and mixed with die-
thylpyrocarbonate (DEPC) dissolved in water. After cen-
trifugation at approximately 12000 rpm at 4 °C for 5 min,
the pellet was dried at room temperature. Finally, the
pellet was dissolved in 30 μL of nuclease-free water
(NFW). The quality and quantity of RNA were estimated
by calculation of OD260/OD280 ratios using a spectro-
photometer. Complementary DNA (cDNA) was synthe-
sized using the RT System kit. The RNA was added to the
oligo dT primer, dNTP mixture, RTase, RNase inhibitor,
and buffer. The generated cDNA was mixed with each
primer, dNTP mixture, Taq polymerase, and reaction
buffer in the PCR tube. PCR conditions consisted of
denaturation at 94 °C for 3 min, followed by 30 cycles each
featuring denaturation at 94 °C for 30 s, annealing at
48–60 °C for 30 s, and elongation at 72 °C for 30 s, and
then, the reaction was maintained at 72 °C for 10min. The
following primer sequences were used: F: GAGGAAG
TCGGTGAAGAACG and R: ATCGAAGGTCTCGATG
TTGG for Sox9; F: TGAGGAGGGCTGGAACAAGT and
R: GGAGGTGGTAATTGCAGGGA for Aggrecan; F: TG
GAGAAACCATCAATGGTGG and R: TGGAGAAACC
ATCAATGGTGG for Type II collagen; F: ATGACCCAA
GGACTGGAATCTTTA and R: ATGACCCAAGGACT
GGAATCTTTA for Type X collagen; F: AAGGGTCCAC
TCTGGCTTTG and R: CTAGGCGCATTTCAGGTGCT
for RUNX2; F: TTTCCCTGGCAAGGACTATG and R:
GGAGGAGAACTGGACACCAC for ADAMTS4; F: TG
ACCATGAGGAGCACTACG and R: TGGGAGAGGCC
AAGTAAATG for ADAMTS5; F: GTGGTGTGGGAAG
TATCATCA and R: GCATCTGGAGTAACCGTATTG
for MMP13; F: GAAACTACTTCCTGAAAACAACGT
and R: GCCTCACAACCTCCGTACT for p53; F: CATG
GGTGTGAACCATGAGA and R: GGTCATGAGTCCT
TCCACGA for GAPDH. PCR products were separated by
electrophoresis on 1.2% (w/v) agarose gels. Gel-Doc was
used to visualize the bands.
Nuclear extraction
The nuclei and cytoplasm of ASCs were extracted using
NE-PER nuclear and cytoplasmic extraction reagents kits
(Thermo Scientific, IL, USA). ASCs were harvested with
trypsin-EDTA and centrifuged at 500 × g for 5 min to
collect the cell pellet. Then, the cell pellet was washed
with PBS, and 1–10 × 106 cells were transferred to a 1.5-
ml microcentrifuge tube and pelleted by centrifugation at
500 × g for 3 min. After the PBS was removed, cyto-
plasmic extraction reagent I (CER I) was added to the cell
pellet. The cell pellet was vortexed to fully suspend it on
the highest setting for 15 s and then incubated on ice for
10min. Then, cytoplasmic extraction reagent II (CER II)
was added to the sample, vortexed for 5 s, placed on ice
for 1 min, vortexed for 5 s, and centrifuged for 5 min at
maximum speed in a microcentrifuge (~16,000 × g). The
supernatant was immediately transferred to a new tube
and stored on ice until use. The supernatant contained
cytoplasmic proteins, and the pellet contained the nuclear
fraction. After addition of ice-cold nuclear extraction
reagent (NER) to the pellet, vortexing for 15 s and incu-
bation on ice for 10min was repeated four times. Then,
the sample was centrifuged at maximum speed in a
microcentrifuge (~16,000 × g) for 10 min, and the
supernatant fraction was transferred to a new tube. The
supernatant included the nuclear extract.
Western blot analysis
The cells were washed with PBS and lysed in lysis buffer
with proteinase and phosphatase inhibitors. Protein con-
centrations were determined using the BCA Protein Assay
Kit. Then, the same concentration of proteins was sepa-
rated on a sodium dodecyl sulfate-polyacrylamide gel and
transferred to a polyvinylidene difluoride membrane.
After the membrane was blocked in 5% skim milk mixed
with 0.1% Tween 20 in TBS buffer for 1 h at room tem-
perature, it was rinsed twice with TBS buffer and incu-
bated with primary antibody overnight at 4 °C. Next, the
membrane was washed three times with 0.1% Tween 20
TBS buffer for 10 min and incubated for 1 h at room
temperature with HRP-conjugated secondary antibodies.
After extensive washing, the bands were detected with an
enhanced chemiluminescence reagent. The band inten-
sities were quantified using NIH ImageJ version 1.34e
software.
ADAMTS4 and ADAMTS5 ELISA verification
The protein activities of ADAMTS4 and ADAMTS5,
which are released as active protease forms in the cell
culture supernatant, were measured using ADAMTS4
and ADAMTS5 ELISA kits (R&D Systems). The
ADAMTS4 and ADAMTS5 capture antibodies were
coated in a 96-well microplate overnight at room tem-
perature. After three washes, blocking with reagent dilu-
ent was performed for 1 h, and the standard and sample
were added and reacted at room temperature for 2 h. The
plate was washed three times, incubated with detection
antibody for 2 h, and washed again. Streptavidin-HRP was
added and reacted for 20min in the dark. After the sub-
strate solution was added for 20min, the reaction was
stopped using stop solution, and the value was read at
450 nm using a microplate reader.
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Transcription factor activation array
Transcription factor activation was measured using a
TF activation profiling plate array and customized array
(Signosis, Inc., CA, USA). The nuclei of ASCs were
extracted using a Nuclear Extraction Kit (Signosis, Inc.).
ASCs were washed with PBS, and then, the Buffer I
working reagent mixture was added for 10min. The ASCs
were removed from the plate using a scraper, transferred
to a microcentrifuge tube and centrifuged at 12000 rpm
for 5 min. The supernatant was discarded completely, and
the Buffer II working reagent mixture was added for 2 h.
The sample was centrifuged at 12,000 rpm for 5 min, and
then, the supernatant was transferred to a new tube. For
TF/DNA complex formation, the TF probe and nuclear
fraction were mixed in a tube for 30min. The TF/DNA
complex was separated from the free probe and incubated
in a hybridization plate overnight. Finally, transcription
factor activity was detected using a luminometer.
Osteoarthritis induction and ASC injection
Osteoarthritis was induced using 250 g male Sprague-
Dawley (SD) rats. Rats were anesthetized by intraper-
itoneal administration of 20 mg/kg Zoletil and 5mg/kg
Rompun. Anesthesia was performed twice by intra-
articular injection for 1 week, where 30 μl of either ster-
ile saline (control group) and 250 U or 500 U of type II
collagenase dissolved in saline and filtered through a 0.22-
μm membrane was injected. ASCs induce differentiation
into chondrocytes after treatment with ELPC for 16 days
prior to injection. One week after the injection of Type II
collagenase, normal ASCs and differentiated ASCs were
injected with 1 × 106 cells in PBS.
Alcian blue staining
Alcian blue is a blue stain associated with the sulfated
glycosaminoglycan of the cartilage matrix. After 16 days,
the cells were rinsed once with PBS and fixed with 4%
Fig. 1 Importance of Sox9 in chondrogenic differentiation. a, b mRNA and protein expression of Sox9 in ASCs and chondrocytes. Normalized by
GAPDH and B-actin. *p < 0.05 compared to ASCs **p < 0.001 compared to ASCs. n= 3. c ASCs were transfected with 50 nM Sox9 siRNA for 24 h and
cultured in chondrocyte differentiation medium (DM). The cells were transfected with the Sox9 siRNA every 3 days for 16 days while cultured in DM.
The mRNA expression of Sox9, Aggrecan, and Type II collagen in the Sox9 siRNA-transfected ASCs. C and Cont control, R reagent-transfected ASCs, siR
Sox9 siRNA-transfected ASCs, DM chondrogenic differentiation induction medium. *p < 0.05, **p < 0.001 compared to the control, #p < 0.05, ##p <
0.001 compared to the reagent-transfected and DM-treated ASCs. n= 3.
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formaldehyde solution for 1 h at room temperature. Then,
Alcian blue staining solution with 3% acetic acid solution
(pH 2.5) was added to each sample for 30min. After
staining, the samples were washed in running tap water
for 2 min and finally mounted with mounting solution.
Safranin O staining
The knee joint paraffin sections were stained using a
safranin O staining kit. First, the section was depar-
affinized, rehydrated, rinsed with tap water and then
stained with 0.1% fast green solution for 5 min. The
sample was rinsed with 1% acetic acid for 10 s and then
stained using 0.1% safranin O staining solution for 30min.
Finally, the section was dehydrated and mounted with
mounting solution.
Immunofluorescence
The knee joint was fixed overnight with 10% (v/v) for-
maldehyde. The knee joint was embedded in paraffin and
transversely sectioned into serial thick sections. After
deparaffinization, rehydration, and rinsing with tap water,
sodium citrate antigen retrieval was performed using
10mM sodium citrate (pH 6.0) in a microwave for 10min.
Sections were incubated in 1% H2O2 to quench endo-
genous peroxidase. The tissue sections were treated with
0.1% sodium borohydride to remove autofluorescence and
Fig. 2 Chemical screening of the Sox9 inducer from a small molecule library. a Vector generation strategy containing the Sox9 promoter region
and a GFP tag. b After the ASCs were transfected with the Sox9 promoter-GFP vector, 1 μM small molecules were added for 24 h. GFP expression was
measured using a fluorescence microplate reader. c Selected candidate small molecules were added to ASCs transfected with the Sox9 promoter-
GFP vector. GFP expression in the ASCs transfected with the Sox9 promoter-GFP vector was observed by fluorescence microscopy. A pEGFP-N1
vector was used as a positive control to evaluate the transfection efficiency. Chondrogenic differentiation medium (DM) was also used as a positive
control to evaluate Sox9 expression. d ASCs were treated with 1 μM of each of the three selected candidate drugs every 3 days for 16 days. The
expression of mature chondrocyte markers (Sox9, Aggrecan, and Type II collagen) and hypertrophic chondrocyte markers (RUNX2 and Type X
collagen) was measured using PCR of the Drug 7-, Drug 51-, and Drug 138-treated ASCs. D DMSO-treated ASCs, *p < 0.01, **p < 0.05, ***p < 0.001
compared to the control. n= 3.
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were blocked in 2.5% normal horse serum. After blocking,
the sections were incubated with primary antibody over-
night. The sections were analyzed for DAPI, Aggrecan,
and collagen type 2 and 10 by an LSM700 confocal laser
scanning microscope.
Statistical analysis
The results are expressed as the mean ± SD from at least
three independent experiments. Statistical analyses were
performed using Student’s t-test. Comparisons between
more than two groups were performed by one-way
ANOVA using Bonferroni’s correction. Relationships
were considered statistically significant when the p-value
was <0.05.
Results
Screening of small molecules that induce the
differentiation of ASCs into chondrocytes
First, we found that the mRNA and protein levels of the
sex-determining region Y-type high mobility group box
(Sox)9 were higher in chondrocytes than in ASCs (Fig. 1a,
b). Next, we confirmed an important role of Sox9 during
the differentiation of ASCs into chondrocytes. The
increased expression of Sox9, Aggrecan, and Type II
Fig. 3 Ellipticine induces chondrogenic differentiation in ASCs. a Structure of ellipticine. b Concentration-dependent cell viability was measured
by cell viability assays in ASCs. D DMSO-treated ASCs *p < 0.05, ***p < 0.001 compared to the control. n= 3. c The ability of ELPC to induce
differentiation was confirmed using Alcian blue staining after ASCs were incubated with ELPC for 16 days. Scale bar: 3 mm. d A 3D pellet culture was
performed using ASCs or ELPC-treated ASCs for 16 days. **p < 0.01 compared to the control. n= 3. e The untreated ASC and ELPC-treated ASC pellets
were stained using Alcian blue and H&E. The expression of Type II collagen, Aggrecan, and Type X collagen was detected by immunofluorescence.
Nuclei were stained with DAPI (Blue). Scale bar: upper 400 μm and lower 50 μm. f The mRNA expression of the extracellular matrix degradation
enzymes ADAMTS4, ADAMTS5, and MMP13. Normalized by GAPDH. *p < 0.05, ***p < 0.001 compared to the control. n= 3. g The concentrations of
secreted ADAMTS4 and ADAMTS5 were measured by ELISAs. ***p < 0.001 compared to the control, #p < 0.001 compared to the 16-day control, $p <
0.001 compared to the ELPC-treated ASCs. C and Cont control, DM chondrogenic differentiation induction medium, ELPC ELPC-treated ASCs. n= 3.
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collagen in the DM-treated ASCs was inhibited in the
Sox9 siRNA-transfected ASCs (Fig. 1c). A specific vector
system containing the Sox9 promoter region and GFP was
used to screen for a drug that increases Sox9 expression
(Fig. 2a). The relative Sox9 expression was analyzed based
on the overexpression of GFP under the treatment of
small molecules (Fig. 2b) and was confirmed using
fluorescence microscopy (Fig. 2c). Finally, three candidate
drugs were selected, and the differentiation capability of
the drugs was determined by the mRNA expression levels
of mature chondrocyte and hypertrophic chondrocyte
markers. The expression levels of Sox9, Aggrecan, and
Type II collagen were increased in the ASCs treated with
each of the three drugs, whereas those of RUNX2 and
Type X collagen were increased in the cells treated with
drugs 7 and 51 and not in the ASCs treated with drug 138,
as shown in Fig. 2d.
ELPC induces chondrocyte differentiation in adipose-
derived stem cells
Drug 138, known as ellipticine (ELPC), is a natural tet-
racyclic compound (Fig. 3a). The cytotoxicity in ASCs
prior to further experiments was investigated; 1 μM ELPC
resulted in a slight reduction in cell viability, and 80% or
more of the ASCs underwent cell death with 10 μM ELPC
(Fig. 3b). To further confirm the ability of ELPC to induce
the differentiation of ASCs into chondrocytes, we per-
formed Alcian blue staining after the ASCs were incubated
with ELPC for 16 days. Figure 3c shows that the ELPC-
treated ASCs had more blue and condensed areas than the
untreated ASCs. The ELPC-treated ASCs maintained
more rounded pellets and a greater diameter and total size
than the untreated ASCs (Fig. 3d). The expression levels of
Aggrecan and Type II collagen were increased in the
ELPC-treated ASC pellets, whereas the expression of Type
X collagen was not increased (Fig. 3e). We also confirmed
that the mRNA levels of ECM-degrading enzymes were
decreased in a time-dependent manner by ELPC treatment
(Fig. 3f). In addition, the levels of ADAMTS4 and
ADAMTS5 were significantly decreased in the medium of
the ELPC-treated ASCs (Fig. 3g).
ELPC increases the expression of Sox9 by regulating p53
during chondrogenesis
We investigated whether ELPC regulates transcription
factors that can bind to the promoter region of Sox9. Sev-
eral transcription factors were selected that were predicted
to bind to the Sox9 promoter region by the PROMO 3.0
program. Among them, p53 was found to be associated
with ELPC (Fig. 4). Therefore, the mRNA and protein levels
of p53 were measured after ELPC treatment. Both the
mRNA and protein levels of p53 increased for up to 24 h
(Fig. 5a, b). The expression of p53 was also evaluated in
isolated nuclear and cytosolic fractions. p53 expression was
shifted to the nucleus (Fig. 5c), and a fluorescent stain of
p53 also showed translocation from the cytoplasm to the
nucleus following ELPC treatment (Fig. 5d). We further
confirmed the association between ELPC and p53. The
expression of p53 was decreased by p53 siRNA (Fig. S1),
which inhibited the expression of Sox9 and Type II collagen
(Fig. 5e, f). In addition to p53, we also investigated whether
AP-2α or C/EBPβ siRNA regulated the expression of Sox9,
resulting in no reduction in mature chondrocyte markers
(data not shown). These results indicate that ELPC induces
Sox9 expression by regulating the expression of p53 during
the chondrogenesis of ASCs.
Protective effects of ELPC in an animal model of
osteoarthritis
A cartilage-protective effect of ELPC-treated ASCs was
observed in an animal model of OA. Decreased cartilage
damage was observed in the ASC- and ELPC-treated
ASC-injected groups (Fig. 6a). The expression levels of
both Type II collagen and Aggrecan were higher than
those of the OA-induced group, while the expression level
of Type X collagen was lower in the ELPC-treated ASC-
injected group than in the ASC-injected group (Fig. 6b).
Discussion
Our results suggest that ELPC can induce ASC differ-
entiation into chondrocytes through upregulation of the
expression of Sox9 by increasing the expression and
activation of p53. Most importantly, ASCs differentiated
by ELPC did not exhibit the characteristics of hyper-
trophic chondrocytes. In these experiments, we used the
Fig. 4 Transcription factors associated with ELPC in the Sox9
promoter region. a Transcription factors binding to the Sox9
promoter were predicted by the PROMO 3.0 program. b Transcription
factor activity, predicted to bind a Sox9 promoter region, was
measured using a TF activation plate array kit (customizing kit,
Signosis).
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Sox9 promoter-GFP vector system to screen small
molecules because Sox9 has a critical role as a tran-
scription factor during cartilaginous skeleton formation in
the early stage of chondrogenesis21–23 and regulates
chondrocyte-specific matrix proteins such as Type II
collagen and Aggrecan24,25. Therefore, we finally chose
ELPC, an alkaloid that was first extracted from the species
Ochrosia elliptica and Rauvolfia sandwicensis. In cancer,
ELPC has been used as a drug to induce cell death
because it inhibits the enzyme topoisomerase II via
intercalative binding to DNA26. Therefore, we assessed
cell viability and found there was no toxicity until 0.5 μM.
In this study, Sox9 overexpression by ELPC treatment was
critical, and p53 was shown to play an important role in
Fig. 5 ELPC-induced mechanism in chondrogenic differentiation. a The mRNA expression of p53 in the ELPC-treated ASCs. ***p < 0.001
compared to the control. n= 3. b The protein expression of p53 in the ELPC-treated ASCs. *p < 0.01, **p < 0.05 compared to the control. n= 3. c The
ASCs treated with ELPC for 24 h were separated into the nuclear and cytosolic fractions. p53 was quantified and normalized to Lamin B2 and α-
tubulin in the nucleus and cytosol, respectively. Cont Control, D DMSO-treated ASCs. *p < 0.01 **p < 0.05 ***p < 0.001 compared to the control. n= 3.
d The translocation of p53 was confirmed by immunofluorescence staining. p53 was detected by FITC green fluorescence. The nucleus was stained
with DAPI (blue). Scale bar: 30 μm. e, f The protein expression levels of Sox9 and Type II collagen in the ELPC-treated ASCs were investigated 24 h
after transfection with 50 nM p53 siRNA. ***p < 0.001 compared to the control, #p < 0.05 compared to the ELPC-treated ASCs. $p < 0.001 compared to
the reagent- and ELPC-treated ASCs. n= 3.
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regulating Sox9 expression. Consequently, ELPC
increased the expression and nuclear translocation of p53.
Most previous studies of ELPC have explored its effects
on various cancers. ELPC inhibited p53 ubiquitination
and increased the nuclear localization of endogenous
p534,27. Another study also demonstrated that ELPC
recovered the transcriptional function of mutant p5327.
Recent studies have confirmed that p53 regulates the
differentiation of embryonic stem cells and induces
pluripotent stem cells in response to genomic damage,
similar to our results28,29.
In vivo studies demonstrated that cartilage damage
could be recovered in rats injected with ASCs differ-
entiated by ELPC. In addition, the indicators of mature
chondrocytes were increased, and indicators of hyper-
trophic chondrocytes were not increased (Fig. 6). The
limitations of this study include a lack of confirmation of
whether differentiated ASCs directly adhere to cartilage to
regenerate or are affected by secreted molecules from
transplanted ASCs. Therefore, further investigation is
needed to confirm these issues. In addition, since there
are stem cells in the synovium, it is also necessary to
confirm the effect of ELPC treatment alone in ameliora-
tion of OA in an in vivo study.
Taken together, the results demonstrate that ELPC
induces differentiation into the appropriate type of
chondrocytes by increasing Sox9 from ASCs, and ELPC
exerted a significant protective effect in an animal model
of OA. These results suggest that ELPC is a potential new
therapeutic drug for OA.
Acknowledgements
This research was supported by grants from the Ministry of Health & Welfare,
Republic of Korea (HI18C0661), and the Basic Science Research Program
through the National Research Foundation of Korea (NRF) funded by the
Ministry of Education (2018R1A6A3A01012013).
Author details
1Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul,
Republic of Korea. 2Institute for Bio-Medical Convergence, College of Medicine,
Catholic Kwandong University, Gangneung, Republic of Korea. 3Department of
Integrated Omics for Biomedical Sciences, Yonsei University, Seoul, Republic of
Korea. 4Department of Medical Engineering, Yonsei University College of
Medicine, Seoul 03722, Republic of Korea
Fig. 6 ELPC-induced mechanism and protective effect in an animal model of OA. a Safranin O staining of the paraffin sections of the OA animal
model. Representative images show cartilage damage after 6 weeks of OA induction. Safranin O binds to glycosaminoglycan in cartilage and is
shown in red. The lower figure shows an enlargement of the cartilage part in the upper figure, scale bar: upper 3 mm and lower 600 μm. Graph
indicating the relative cartilage thickness. ***p < 0.001 compared to the normal control, ###p < 0.001 compared to the animal model of OA. n= 3.
b Detection of mature and hypertrophic chondrocyte markers in the OA animal model. Type II collagen (FITC, green), aggrecan (Texas red, red), and
type X collagen (rhodamine, orange) expression was measured by immunofluorescence staining and visualized with a confocal microscope. Each
section was costained with DAPI (blue) for nuclear staining. The images in the same region of tissue were merged into the overlapped image. Scale
bar: 60 μm.
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